KMKathryn Anne Martinez

Kathryn Anne Martinez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathryn Anne Martinez has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Racial Differences in Respiratory Tract Infection Diagnosis and Antibiotic Prescriptions

    by Kathryn A. Martinez, Ava Rezaee, Victoria Criswell, Michael B. Rothberg

    Background: Non-White patients are less likely than White patients to be prescribed antibiotics for respiratory tract infections (RTIs). Our objective was to understand whether this could be explained by differences in RTI diagnosis type by race. Methods: We conducted an observational cohort study of adults receiving urgent care at Cleveland Clinic in Northeast Ohio who were diagnosed with an RTI between 2016 and 2022. We used mixed effects logistic regression of antibiotic prescription by patient race (White versus non-White) in two models: 1) not accounting for RTI diagnosis type, and 2) accounting for diagnosis type. We used mixed effects logistic regression, including physician and individual patient as random effects, to assess differences in the odds of being diagnosed with sinusitis versus unspecified RTI by race. Finally, we assessed odds of being prescribed an antibiotic by race, stratified by diagnosis. Analyses were conducted at the visit level. Results: Among 100,052 visits with 62,972 unique patients (median visits per patient was 1), 21% percent were for sinusitis and 30% were for unspecified RTI. Eighty-four percent of patients were White and 16% were non-White. In the model not controlling for diagnosis, compared to White patients, non-White patients were significantly less likely to be prescribed an antibiotic (aOR: 0.79; 95%CI:0.76–0.82). After adjusting for diagnosis, the association between non-White race and antibiotic prescription was weaker but still significant (aOR:0.91; 95%CI:0.87–0.95). Compared to White patients, non-White patients were significantly less likely to be diagnosed with sinusitis versus unspecified RTI (aOR:0.61; 95%CI:0.56–0.66). Non-White patients were significantly less likely to be prescribed antibiotics for sinusitis and unspecified RTI than White patients. Conclusions: Racial differences in diagnosis of sinusitis partially explain lower rates of antibiotic prescription among non-White patients.

  • Open Access

    Breaking the Genetic Counseling Bottleneck in BRCA Testing

    by Kathryn A. Martinez, Michael B. Rothberg

  • Variation in HIV Pre-exposure Prophylaxis (PrEP) Adherence by Area Deprivation Index

    by Jeffrey Shu, Leila Momtazi-Mar, Jeffrey D. Kovach, Henry Ng, Kathryn A. Martinez

  • Association between Exposure to Statin Choice and Adherence to Statins: An Observational Cohort Study

    by Kathryn A. Martinez, Victor M. Montori, Fatima Rodriguez, Larisa G. Tereshchenko, Jeffrey D. Kovach, Christopher Boyer, Heather McKee Hurwitz, Michael B. Rothberg

    Background: Statin Choice is a shared decision-making encounter tool embedded in the electronic health record. Objective: To describe the association between the use of Statin Choice, statin prescriptions by clinicians, prescription fills (primary adherence), and statin adherence at 12 mo (secondary adherence). Design: Observational cohort study at the Cleveland Clinic Health System. Subjects: Statin-naïve adults aged 40 to 75 y with a 10-y atherosclerotic cardiovascular disease (ASCVD) risk of ≥5% and a primary care appointment between January 2020 and July 2021. Main Measures: The primary exposure was the use of Statin Choice during a clinical encounter. We measured whether the use of Statin Choice was associated with statin prescriptions. We measured statin adherence based on pharmacy fill data at 60 d (primary adherence) and 12 mo (secondary adherence). We used mixed-effects logistic regression to estimate the adjusted odds of statin prescriptions and adherence at the 3 time points by the use of Statin Choice. Key Results: Among 17,001 statin-naïve patients, 13% viewed Statin Choice and 7% were prescribed a statin. The median ASCVD risk was 10%. Patients who were shown Statin Choice had 9.04 higher odds of being prescribed a statin compared with patients not shown Statin Choice (95% confidence interval [CI]: 7.86–10.4). Among patients prescribed a statin, the use of Statin Choice was associated with 5.75 higher odds of primary adherence compared with usual care (95% CI: 4.22–7.83). At 12 mo, Statin Choice use was significantly associated with adherence in the unadjusted analysis (OR: 1.58; 95% CI: 1.05–2.08) but was not significant after adjustment for patient factors. Patients shown Statin Choice had an average of 12 mg/dL reduction in low-density lipoprotein cholesterol at 12 mo (95% CI: −16 mg/dL, −10) compared with those not shown Statin Choice. Conclusion: In this observational study, Statin Choice use was strongly associated with statin prescription and fills and weakly associated with adherence to statins for up to 1 y. A randomized trial is needed to confirm causality. Highlights: Statin Choice is an electronic health record–embedded shared decision-making encounter tool available for free in many health care systems. Small randomized controlled trials have found modest associations between the use of Statin Choice and statin adherence using patient-reported data. In our large study using pharmacy fill data, clinician use of Statin Choice during a medical encounter was associated with significantly greater patient adherence with statins up to 1 y later. Exposure to Statin Choice was associated with a significant reduction in low-density lipoprotein cholesterol over 1 y.


  • Clinician Response to the 2021 USPSTF Recommendation for Colorectal Cancer Screening in Average Risk Adults Aged 45–49 Years

    by Joseph Carter Powers, Michael B. Rothberg, Jeffrey D. Kovach, Nicholas J. Casacchia, Elizabeth Stanley, Kathryn A. Martinez


  • Open Access

    Building expert consensus regarding sharing of individual research results in Alzheimer’s disease research: a Delphi study protocol

    by Lauren R Sankary, Valerie Rico, Megan Zelinsky, Helen S Webster, Alan J Lerner, Kathryn Martinez, Paul J Ford, Babak Tousi, James Leverenz

    Introduction Informed decisions to enrol in the clinical investigations of Alzheimer’s disease and related dementias (ADRD) require careful consideration of complex risks and uncertain benefits. Decisions regarding whether to receive information about biomarker status are complicated by lack of scientific consensus regarding biomarkers as surrogate endpoints for Alzheimer’s disease and how information about individual risk should be evaluated and shared with research participants. This study aims to establish stakeholder consensus regarding ethically optimal approaches to sharing individual results with ADRD research participants. Methods and analysis This Delphi consensus-building study consists of multiple online surveys conducted with Alzheimer’s disease research experts, including neurologists, neuropsychologists, ethicists, research oversight specialists and clinical trialists. Panellists will be administered questionnaires developed from a synthesis of researcher- and participant-endorsed considerations and decisional needs identified in published literature and a decisional needs assessment conducted with support from an Alzheimer’s Association Research Grant. Panellists will also be asked their views on the content and implementation of processes for sharing individual research results. ≥75% agreement will be required to achieve consensus. Response rates, level of agreement, medians, interquartile ranges and group rankings will be analysed. Following each round of data collection, our research team will undertake qualitative content analysis of open-ended responses. Ethics and dissemination Ethical approval will be obtained from the Cleveland Clinic Institutional Review Board (Study Number 22–766). Delphi panellists will receive participant information sheets describing the study before agreeing to participate in the Delphi process. Results from the data we anticipate will be generated through this research and will be submitted for peer-reviewed journal publication and presentation at international conferences.


  • Antibiotic Prescribing for Respiratory Tract Infections in Urgent Care: A Comparison of In-Person and Virtual Settings

    by Kathryn A Martinez, Abhishek Deshpande, Elizabeth Stanley, Michael B Rothberg

    Background: Little is known about antibiotic prescribing for respiratory tract infections (RTIs) in virtual versus in-person urgent care. Methods: In this retrospective study, we used electronic health record data from Cleveland Clinic Health System. We identified RTI patients via International Classification of Diseases, Tenth Revision, Clinical Modification, codes and assessed whether the visit resulted in an antibiotic. We described differences in diagnoses and prescribing by setting (virtual versus in-person). We used mixed effects logistic regression to model the odds of antibiotic receipt by urgent care setting. We applied the model first to all physicians and second only to those who saw patients in both settings. Results: There were 69 189 in-person and 19 003 virtual visits. Fifty-eight percent of virtual visits resulted in an antibiotic compared with 43% of in-person visits. Sinusitis diagnoses were more than twice as common in virtual versus in-person care (36% vs 14%) and were associated with high rates of prescribing in both settings (95% in-person, 91% virtual). Compared with in-person care, virtual urgent care was positively associated with a prescription (odds ratio, 1.64; 95% confidence interval [CI]: 1.53–1.75). Among visits conducted by 39 physicians who saw patients in both settings, odds of antibiotic prescription in virtual care were 1.71 times higher than in in-person care (95% CI: 1.53–1.90). Conclusions: Antibiotic prescriptions were more common in virtual versus in-person urgent care, including among physicians who provided care in both platforms. This appears to be related to the high rate of sinusitis diagnosis in virtual urgent care.


  • Clinician use of the Statin Choice Shared Decision-making Encounter Tool in a Major Health System

    by Kathryn A. Martinez, Victor M. Montori, Fatima Rodriguez, Larisa G. Tereshchenko, Jeffrey D. Kovach, Heather McKee Hurwitz, Michael B. Rothberg

    Background Effective shared decision-making (SDM) tools for use during clinical encounters are available, but, outside of study settings, little is known about clinician use of these tools in practice. Objective To describe real-world use of an SDM encounter tool for statin prescribing, Statin Choice, embedded into the workflow of an electronic health record. Design Cross-sectional study. Participants Clinicians and their statin-eligible patients who had outpatient encounters between January 2020 and June 2021 in Cleveland Clinic Health System. Main Measures Clinician use of Statin Choice was recorded within the Epic record system. We categorized each patient’s 10-year atherosclerotic cardiovascular disease risk into low (< 5%), borderline (5–7.5%), intermediate (7.5–20%), and high (≥ 20%). Other patient factors included age, sex, insurance, and race. We used mixed effects logistic regression to assess the odds of using Statin Choice for statin-eligible patients, accounting for clustering by clinician and site. We generated a residual intraclass correlation coefficient (ICC) to characterize the impact of the clinician on Statin Choice use. Key Results Statin Choice was used in 7% of 68,505 eligible patients. Of 1047 clinicians, 48% used Statin Choice with ≥ 1 patient, and these clinicians used it with a median 9% of their patients (interquartile range: 3–22%). In the mixed effects logistic regression model, patient age (adjusted OR per year: 1.04; 95%CI 1.03–1.04) and 10-year ASVCD risk (aOR for 5–7.5% versus < 5% risk: 1.28; 95%CI: 1.14–1.44) were associated with use of Statin Choice. Black versus White race was associated with a lower odds of Statin Choice use (aOR: 0.83; 95%CI: 0.73–0.95), as was female versus male sex (aOR: 0.83; 95%CI: 0.76–0.90). The model ICC demonstrated that 53% of the variation in use of Statin Choice was clinician-driven. Conclusions Patient factors, including race and sex, were associated with clinician use of Statin Choice; half the variation in use was attributable to individual clinicians.


  • Open Access

    Building Stakeholder Consensus Regarding Disclosure of Individual Research Results in ADRD Research: A Delphi Study Protocol

    by Lauren R Sankary, Megan Zelinsky, Alan J. Lerner, Kathryn Martinez, Justin B Miller, James B Leverenz

    Background: Informed decisions to enroll in clinical investigations of Alzheimer’s disease and related dementias (ADRD) require careful consideration of complex risks and uncertain benefits. Decisions regarding scope of research participation and whether to receive information about biomarker status are complicated by lack of scientific consensus regarding biomarkers as surrogate end points for Alzheimer’s disease. This Delphi protocol aims to establish stakeholder consensus regarding the content and features of ethically optimal informed consent support for ADRD research.Method: This consensus‐building Delphi protocol consists of three rounds of online surveys conducted with three stakeholder groups: Alzheimer’s disease research experts (including ethicists, research oversight specialists, and clinical trialists), Alzheimer’s disease research participants, and study partners of individuals enrolled in ADRD research. Participants will be administered questionnaires developed from a synthesis of researcher‐ and participant‐endorsed decisional needs identified in published literature and a decisional needs assessment conducted with support from an Alzheimer’s Association Research Grant. Participants will also be asked their views on the design, content, and implementation of a decision support tool. ≥70% agreement will be required to achieve consensus. Response rates, level of agreement, medians, interquartile ranges, and group rankings will be analyzed. Following each round of data collection, our research team will undertake qualitative content analysis of open‐ended responses and forum interactions.Result: This protocol will develop consensus regarding priorities for decision support for ADRD research participants and the key features and content of ethically optimal informed consent support interventions. The Delphi technique is appropriate to develop consensus between diverse stakeholders because of its ability to offer anonymity to other participants and minimize bias.Conclusion: Findings will contribute to the development of a digital health research infrastructure that is inclusive of diverse individuals and attentive to the needs of cognitively vulnerable patient populations and their caregivers.

  • Patient Portal Message Volume and Time Spent on the EHR: an Observational Study of Primary Care Clinicians

    by Kathryn A. Martinez, Rebecca Schulte, Michael B. Rothberg, Maria Charmaine Tang, Elizabeth R. Pfoh

    Background As patient-initiated messaging rises, identifying variation in message volume and its relationship to clinician workload is essential. Objective To describe the association between variation in message volume over time and time spent on the electronic health record (EHR) outside of scheduled hours. Design Retrospective cohort study. Participants Primary care clinicians at Cleveland Clinic Health System. Main Measures We categorized clinicians according to their number of quarterly incoming medical advice messages (i.e., message volume) between January 2019 and December 2021 using group-based trajectory modeling. We assessed change in quarterly messages and outpatient visits between October–December 2019 (Q4) and October–December 2021 (Q12). The primary outcome was time outside of scheduled hours spent on the EHR. We used mixed effects logistic regression to describe the association between incoming portal messages and time spent on the EHR by clinician messaging group and at the clinician level. Key Results Among the 150 clinicians, 31% were in the low-volume group (206 messages per quarter per clinician), 47% were in the moderate-volume group (505 messages), and 22% were in the high-volume group (840 messages). Mean quarterly messages increased from 340 to 695 (p < 0.001) between Q4 and Q12; mean quarterly outpatient visits fell from 711 to 575 (p = 0.005). While time spent on the EHR outside of scheduled hours increased modestly for all clinicians, this did not significantly differ by message group. Across all clinicians, each additional 10 messages was associated with an average of 12 min per quarter of additional time spent on the EHR (p < 0.001). Conclusions Message volume increased substantially over the study period and varied by group. While messages were associated with additional time spent on the EHR outside of scheduled hours, there was no significant difference in time spent on the EHR between the high and low message volume groups.